English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The problem of inadequate supply of yellow fever vaccine (YFV) is recurrent, due to a combination of limited production capacity and expansion of circulation of the yellow fever virus. In 2009 Bio-Manguinhos did a dose-response study with the YFV, administrated in the usual mean dose of 27,476 IU and in decreasing doses (10,447 IU, 3013 IU, 587 IU, 158 IU and 31 IU), by the usual subcutaneous route and usual volume (0.5mL). The decreasing doses were obtained by dilution in the laboratory of the manufacturer and the lots in test had industrial quality. Around 30 days after the vaccination, doses down to 587 IU had similar immunogenicity to the full dose. Seropositivity was maintained for 10 months in these doses. Eight years after that dose-response study, at least 80% of the subjects who had seroconverted after yellow fever vaccination with doses from 27,476 IU down to 31 IU. Seropositivity and antibody titers in the reduced-dose groups were comparable to that of the full dose. To complete this issue, a 10 years-duration of immunity study was done.

Duration of immunity in volunteers ten years after a dose-response yellow fever vaccine study